This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Williams SG , Buyyounouski MK , Pickles T , Kestin L , Martinez A , Hanlon AL , Duchesne GM
Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance
International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4) :1169-1175
AbstractPurpose: To define and incorporate the impact of the percentage of positive biopsy cores (PPC) into a predictive model of prostate cancer radiotherapy biochemical outcome. Methods and Materials: The data of 3264 men with clinically localized prostate cancer treated with external beam radiotherapy at four institutions were retrospectively analyzed. Standard prognostic and treatment factors plus the number of biopsy cores collected and the number positive for malignancy by transrectal ultrasound-guided biopsy were available. The primary endpoint was biochemical failure (bF, Phoenix definition). Multivariate proportional hazards analyses were performed and expressed as a nomogram and the model's predictive ability assessed using the concordance index (c-index). Results: The cohort consisted of 21% low-, 51% intermediate-, and 28% high-risk cancer patients, and 30% had androgen deprivation with radiotherapy. The median PPC was 50% (interquartile range [IQR] 29-67%), and median follow-up was 51 months (IQR 29-71 months). Percentage of positive biopsy cores displayed an independent association with the risk of bF (p = 0.01), as did age, prostate-specific antigen value, Gleason score, clinical stage, androgen deprivation duration, and radiotherapy dose (p < 0.001 for all). Including PPC increased the c-index from 0.72 to 0.73 in the overall model. The influence of PPC varied significantly with radiotherapy dose and clinical stage (p = 0.02 for both interactions), with doses <66 Gy and palpable tumors showing the strongest relationship between PPC and bF. Intermediate-risk patients were poorly discriminated regardless of PPC inclusion (c-index 0.65 for both models). Conclusions: Outcome models incorporating PPC show only minor additional ability to predict biochemical failure beyond those containing standard prognostic factors. (C) 2008 Elsevier Inc.
NotesISI Document Delivery No.: 273PB Times Cited: 0 Cited Reference Count: 33 Cited References: ASSMANN SF, 2000, LANCET, V355, P1064 BAHNSON RR, 2000, ONCOLOGY HUNTINGT, V14, P111 BUYYOUNOUSKI MK, 2005, AM SOC THER RAD ONC BUYYOUNOUSKI MK, 2005, INT J RADIAT ONCOL, V63, P1455 COX JD, 1997, INT J RADIAT ONCOL, V37, P1035 DAMICO AC, 2004, J CLIN ONCOL, V22, P3726 DAMICO AV, 2000, J CLIN ONCOL, V18, P1164 DAMICO AV, 2001, INT J RADIAT ONCOL, V49, P679 DAMICO AV, 2002, INT J RADIAT ONCOL, V53, P581 FREEDLAND SJ, 2002, J UROLOGY 1, V167, P516 FREEDLAND SJ, 2003, J UROLOGY, V169, P2136 FREEDLAND SJ, 2004, J UROLOGY 1, V171, P2215 GREENLAND P, 2005, ARCH INTERN MED, V165, P2454 HARRELL FE, 1996, STAT MED, V15, P361 KATTAN MW, 2003, J CLIN ONCOL, V21, P3573 KATTAN MW, 2003, J NATL CANCER I, V95, P634 KATTAN MW, 2004, CLIN CANCER RES, V10, P822 KESTIN LL, 2002, INT J RADIAT ONCOL, V53, P304 KESTIN LL, 2002, J UROLOGY, V168, P1994 MERRICK GS, 2004, CANCER J, V10, P54 PAPAGIKOS MA, 2007, AM J CLIN ONCOL-CANC, V30, P199 PEPE MS, 2004, AM J EPIDEMIOL, V159, P882 PICKLES T, 2003, INT J RADIAT ONCOL, V57, P11 PILEPICH MV, 2001, INT J RADIAT ONCOL, V50, P1243 POLLACK A, 2002, INT J RADIAT ONCOL, V53, P1097 ROACH M, 2006, INT J RADIAT ONCOL, V65, P965 ROYSTON P, 2004, STAT MED, V23, P2509 SIMON EP, 2001, INT J CLIN EXP HYP, V49, P56 STEPHENSON AJ, 2006, J NATL CANCER I, V98, P715 WARE JH, 2006, NEW ENGL J MED, V355, P2615 WILLIAMS SG, 2004, INT J RADIAT ONCOL, V58, P11 WILLIAMS SG, 2006, INT J RADIAT ONCOL, V65, P351 WONG WW, 2004, INT J RADIAT ONCOL, V60, P24 Williams, S. G. Buyyounouski, M. K. Pickles, T. Kestin, L. Martinez, A. Hanlon, A. L. Duchesne, G. M. ELSEVIER SCIENCE INC; 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA